微小RNA作为1A型腓骨肌萎缩症生物标志物
该研究通过下一代测序筛选1A型腓骨肌萎缩症(CMT1A)与对照血浆,发现多种肌肉相关微小RNA(myomiRs)及施万细胞高表达微小RNA升高,并经定量PCR验证,与蛋白标志物及临床数据相关,提示其可作为CMT1A临床试验的候选生物标志物。
要点
- CMT1A患者血浆中miR1、-133a、-133b、-206等myomiRs及施万细胞相关miRs升高。
- 部分miRs(如miR133a、-206、-223)升高程度与神经丝轻链可比,能区分病例与对照。
- 施万细胞相关miRs与TMPRSS5蛋白标志物相关,可能反映疾病病理过程。
核心结论
- 鉴定出一组血浆微小RNA可作为CMT1A临床试验的候选生物标志物。
- 部分微小RNA可能反映施万细胞参与CMT1A发病的过程。
研究设计与样本
- 研究采用下一代测序对CMT1A和对照血浆样本进行微小RNA筛选,随后用定量PCR验证选定微小RNA,并与蛋白标志物及临床数据(Rasch修饰的CMT检查和神经病评分、尺神经复合肌肉动作电位、运动神经传导速度)进行相关性分析。
主要发现
- 初筛后更广泛筛选证实肌肉相关微小RNA(miR1、-133a、-133b、-206,即myomiRs)及一组在周围神经施万细胞高表达的微小RNA水平升高。
- 与同一批样本中其他候选生物标志物(如神经丝轻链)比较,若干微小RNA(如miR133a、-206、-223)升高程度相当,并能区分病例与对照。
- 神经丝轻链水平与miR133a相关性最高;推测的施万细胞微小RNA(如miR223、-199a、-328、-409、-431)与最近描述的TMPRSS5蛋白标志物相关,后者在施万细胞高表达且在CMT1A血浆中升高。
关键数值与推荐
- 本研究提供III级证据表明CMT1A患者血浆中一组微小RNA升高。
临床怎么用
- 这些微小RNA有望作为CMT1A临床试验中的生物标志物,用于监测疾病活动或治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether microRNAs (miRs) are elevated in the plasma of individuals with the inherited peripheral neuropathy Charcot-Marie-Tooth disease type 1A (CMT1A), miR profiling was employed to compare control and CMT1A plasma. METHODS: We performed a screen of CMT1A and control plasma samples to identify miRs that are elevated in CMT1A using next-generation sequencing, followed by validation of selected miRs by quantitative PCR, and correlation with protein biomarkers and clinical data: Rasch-modified CMT Examination and Neuropathy Scores, ulnar compound muscle action potentials, and motor nerve conduction velocities. RESULTS: After an initial pilot screen, a broader screen confirmed elevated levels of several muscle-associated miRNAs (miR1, -133a, -133b, and -206, known as myomiRs) along with a set of miRs that are highly expressed in Schwann cells of peripheral nerve. Comparison to other candidate biomarkers for CMT1A (e.g., neurofilament light) measured on the same sample set shows a comparable elevation of several miRs (e.g., miR133a, -206, -223) and ability to discriminate cases from controls. Neurofilament light levels were most highly correlated with miR133a. In addition, the putative Schwann cell miRs (e.g., miR223, -199a, -328, -409, -431) correlate with the recently described transmembrane protease serine 5 (TMPRSS5) protein biomarker that is most highly expressed in Schwann cells and also elevated in CMT1A plasma. CONCLUSIONS: These studies identify a set of miRs that are candidate biomarkers for clinical trials in CMT1A. Some of the miRs may reflect Schwann cell processes that underlie the pathogenesis of the disease. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a set of plasma miRs are elevated in patients with CMT1A.
引用
- Wang H, Davison M, Wang K, et al. MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A. Neurology. 2021. PMID: 34031204. doi:10.1212/WNL.0000000000012266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。